Project Grant R01EY037726
- The National Eye Institute, part of the Department of Health and Human Services, awarded $458,288 to the University of Washington on May 1, 2026, under the Vision Research program (CFDA 93.867, Assistance Listing designation Project Grant). The award funds research into stimulation of regeneration in the human retina. The investigator team will test whether expressing the proneural regulatory gene ASCL1 in Müller glia can induce regeneration of retinal neurons in human tissue and adult non-human...
- The National Eye Institute, part of the Department of Health and Human Services National Institutes of Health, awarded the University of Wisconsin–Madison $689,706 on August 1, 2026, under the Vision Research program (CFDA 93.867) to establish human stem cell-derived retinal organoids as functional models of human retina for studying disease and testing therapies. The award funds research to identify and overcome limitations in retinal organoids derived from human pluripotent stem cells....
- The National Eye Institute, part of the Department of Health and Human Services National Institutes of Health, awarded the University of Washington $427,625 on June 1, 2026, under the Vision Research program (CFDA 93.867, Assistance Listing Project Grant R21EY038886). The award funds research to decode time-dependent nonlinearities underlying retinal responses to natural stimuli, with particular emphasis on bipolar cell synapses and their role in synaptic plasticity and pathway convergence....
- The National Eye Institute awarded the University of Washington $801,202 on August 1, 2026, under the Vision Research program (CFDA 93.867) to investigate the mechanisms underlying saccadic suppression—the attenuation of visual perception during eye movements. The research examines how much signal loss occurs in the eye versus the lateral geniculate nucleus (LGN) by simultaneously recording from identified retinal ganglion cell axons and their postsynaptic targets in the LGN using high-density...
- The National Eye Institute awarded the University of Washington $503,525 under the Vision Research program (CFDA 93.867) on May 1, 2026, to investigate direction-specific processing in the cerebellar oculomotor vermis during saccadic eye movements. The research addresses how mossy fiber inputs to the cerebellar cortex are transformed by Purkinje cells to generate motor output that fine-tunes saccadic commands. The recipient will conduct optogenetic recordings and neural manipulation studies in...
- The National Eye Institute awarded Duke University $405,373 on June 1, 2026, under the Vision Research program (CFDA 93.867) to characterize bicornuate cones, a novel type of cone photoreceptor cell discovered in the human retina that contains two fully developed outer segments emanating from a single inner segment. The project will conduct two specific aims. Aim 1 employs high-resolution ultrastructural analysis using three-dimensional electron tomography to determine the number of centrioles...
- The National Eye Institute awarded Massachusetts Eye and Ear Infirmary $663,406 on April 1, 2026, under the Vision Research program (CFDA 93.867) to elucidate the molecular mechanisms of secondary cone degeneration in models of retinitis pigmentosa. The recipient will develop a novel AAV-based retinoic acid signaling activator and test whether it can improve photopic visual acuity in multiple mouse models of retinitis pigmentosa. The work will also aim to elucidate the molecular and cellular...
- The National Eye Institute awarded Oregon Health & Science University $498,180 on September 1, 2026, under the Vision Research program (CFDA 93.867) to develop and apply novel optical coherence tomography (OCT) methods for detecting and monitoring photoreceptor changes associated with age-related macular degeneration. The project runs through August 31, 2030, with performance based in Portland, Oregon. Aim 1 investigates cone photoreceptor function impairments in AMD through advancement of...
- The National Eye Institute awarded The University of Iowa $440,263 on May 1, 2026, under the Vision Research program (CFDA 93.867) to investigate osmotic regulation in cone dystrophy with supernormal rod response (CDSRR), a rare inherited retinal disease causing progressive vision loss beginning in early childhood. The project uses state-of-the-art imaging biomarkers and transcriptomics to evaluate osmotic regulation in mouse models of CDSRR, a disease caused by mutations in the KV2.1/KV8.2...
- The National Eye Institute awarded West Virginia University Research Corporation $420,750 on September 1, 2026, under the Vision Research program (CFDA 93.867) to investigate molecular regulators of cone opsin trafficking in the retina. The recipient will identify, characterize, and validate novel OPN1MW (medium-wavelength cone opsin) trafficking partners using two innovative knock-in mouse models. In the first aim, researchers will use OPN1MW.ALFA knock-in mice to isolate stable, direct opsin...
The National Eye Institute awarded the University of Washington $622,804 under the Vision Research program (CFDA 93.867) on August 1, 2026, to establish the cellular and molecular basis of the cone optoretinogram and standardize methods for clinical application. The cone optoretinogram measures length changes of individual human cone outer segments at nanometer-millisecond scale in response to light, using adaptive optics and optical coherence tomography. The research aims to develop high-resolution imaging paradigms for clinical standardization and test mechanistic hypotheses about the optoretinogram's origin, including three distinct components hypothesized to arise from photoisomerization, phototransduction amplification, and the visual cycle. Work is performed in Seattle, Washington with a period of performance ending March 31, 2030. The University of Washington's Office of Sponsored Programs administers the award as the recipient. The optoretinogram offers promise for non-invasive assessment of normal cone function, disease progression, and treatments in living human eyes at cellular resolution, supporting development of therapies to repair or regenerate photoreceptors in age-related and inherited retinal disease.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $622.8k | 7/27/26 |